Tirzepatide leads to significantly greater weight loss than semaglutide in overweight or obese adults, with no significant difference in gastrointestinal adverse effects.
By Dr. Chinta SidharthanReviewed by Susha Cheriyedath, M.Sc.Jul 10 2024 In a recent study published in JAMA Internal Medicine , researchers compared the weight loss and gastrointestinal adverse event rates for obese or overweight adults undergoing treatment with the medications semaglutide or tirzepatide, which are both currently labeled for clinical use for type 2 diabetes .
However, recent randomized clinical trials have reported significant weight loss associated with newer medications such as semaglutide, which is a glucagon-like peptide 1 receptor agonist, and tirzepatide, also a or GLP-1 receptor agonist and a gastric inhibitory polypeptide agonist, among obese individuals irrespective of type 2 diabetes status.
The researchers believe that because both medications are expensive, and most health insurance companies will not cover these medications for obese or overweight individuals who do not have type 2 diabetes, the adherence to these treatments might vary in the clinical setting. Related StoriesThe study used electronic health record data consisting of demographic information, diagnoses, medication prescription information, vital measurements, laboratory test results, and surgical procedures for the analyses. Additional information on social drivers of health and medication dispensing information was also used for the study.
Results The findings suggested that tirzepatide treatment in a clinical population resulted in significantly greater weight loss in overweight or obese individuals than semaglutide treatment, irrespective of the occurrence of type 2 diabetes.
Weight Loss Agonist Diabetes Glucagon Medicine Mortality Obesity Receptor Type 2 Diabetes
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study show tirzepatide beneficial for resolution of MASH in patients with MASH, fibrosisFor patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for resolution of MASH, according to a study published online June 8 in the New England Journal of Medicine to coincide with the annual congress of the European Association for the Study...
Weiterlesen »
New drug tirzepatide significantly improves sleep apnea and weight lossThe effects of tirzepatide on adults with obesity and moderate-to-severe obstructive sleep apnea.
Weiterlesen »
Study identifies first drug therapy for sleep apneaResearchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of...
Weiterlesen »
Study identifies first drug therapy for sleep apneaResearchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of...
Weiterlesen »
FREE STREAM: Watch Chris Billam-Smith and Richard Riakporhe weigh in for cruiserweight world title fightChris Billam-Smith and Richard Riakporhe weigh in for cruiserweight world title fight - watch a live stream here!
Weiterlesen »
Ben Whittaker grabs opponent by throat in physical altercation as rival throws bra at weigh-in...Boxing star Ben Whittaker grabs Ezra Arenyeka by throat in physical altercation during heated weigh-in
Weiterlesen »